American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S367-S372 , December 2008

The clinical content of preconception care: the use of medications and supplements among women of reproductive age

  • Anne L. Dunlop, MD, MPH

      Affiliations

    • Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA
    • ,
  • Paula M. Gardiner, MD, MPH

      Affiliations

    • Department of Family Medicine, Boston University Medical Center, Boston, MA
    • ,
  • Cynthia S. Shellhaas, MD, MPH

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Director for Bureau of Child and Family Health Services, State of Ohio, OH
    • ,
  • M. Kathryn Menard, MD, MPH

      Affiliations

    • Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Melissa A. McDiarmid, MD, MPH

      Affiliations

    • University of Maryland, Occupational Health Program, Baltimore, MD

Received 17 June 2008 ,Accepted 29 July 2008.

References 

  1. Splinter MY, Sagraves R, Nightengale B, Rayburn WF. Pre-natal use of medications by women giving birth at a university hospital. South Med J. 1997;90:498–502
  2. Matt DW, Borzelleca JF. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In:  Witorsch RJ editors. Reproductive toxicology. 2nd ed.. New York: Raven; 1995;p. 175–193
  3. United States Department of Health and Human Services, Health Research Services Administration, Maternal and Child Health Bureau. Women's Health USA 2002. Rockville, Md: 2004.
  4. Kochanek KD, Smith BL. Deaths: preliminary data for 2002 (National vital statistics reports; vol 52 no 13). Hyattsville, Maryland: National Center for Health Statistics; 2004;
  5. Czeizel AE, Intödy Z, Modell B. What proportion of congenital abnormalities can be prevented?. Br Med J. 1996;306:499–503
  6. Nielsen GL, Norgaard B, Puho E, Rothman KJ, Sørensen HT, Czeizel AE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med. 2005;22:693–696
  7. Alexander S, Doods L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998;92:435–440
  8. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369–377
  9. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1–100No. RR-11
  10. Centers for Disease Control and Prevention. US Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. MMWR Morb Mortal Wkly Rep. 2002;51(RR18):1–38
  11. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832–1835
  12. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Gent. 1996;72:179–183
  13. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. Br J Med. 1993;306:1645–1648
  14. Rutledge JC. Developmental toxicity induced during early stages of mammalian embryogenesis. Mutat Res. 1997;396:113–127
  15. Brent RL. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics. 2004;1134(Suppl 4):957–968
  16. Uhl K. Conducting clinical pharmacology studies in pregnant and lactating women. In:  Sahajwalla CG editors. New drug development: regulatory paradigms for clinical pharmacology and biopharmaceutics. New York: Marcel Dekker, Inc; 2004;p. 267–296
  17. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health. 2005;14:104–109
  18. FDA classification of drugs for teratogenic risk (Teratology Society Public Affairs Committee). Teratology. 1994;49:446–447
  19. Department of Health and Human Services, Food and Drug Administration. 21 CFR Part 201: content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Docket No. FDA 2006-0515. Federal Register Vol 73, No. 104, Page 4.
  20. Briggs GG, Freeman RL, Yaffee SJ. Drugs in pregnancy and lactation (Ref. ed.). Philadelphia: Lippincott, Williams, and Wilkins; 2002;
  21. Schwarz EB, Jaselli J, Norton M, Gonzales R. Prescription of teratogenic medications in United States ambulatory practices. Am J Med. 2005;118:1240–1249
  22. American Diabetes Association. Preconceptional care of women with diabetes. Diabetes Care. 2004;27(Suppl 1):S76–S78
  23. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  24. American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:944–948
  25. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457–469
  26. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633–1652
  27. National Asthma Education and Prevention Program. Managing asthma during pregnancy: recommendations for pharmacologic treatment. Bethesda (MD): National Heart, Lung, and Blood Institute; 2005;
  28. Mahadevan U, Kane S. American Gastroenterological Association Institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:278–282
  29. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR-11):1–77
  30. Diamond M. Special treatment situations: menstrual migraine and menstrually-related migraine. Standards of care for headache diagnosis and treatment. Chicago (IL): National Headache Foundation; 2004;
  31. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(Suppl 4):1–50
  32. Committee on Drugs. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105:880–887
  33. Paxil and the risk of birth defects. FDA Consumer. 2006;40:4
  34. Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol. 1991;165:33–40
  35. Weler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology. 1992;45:361–367
  36. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160:339–349
  37. Ervin RB, Wright JD, Reed-Gillette D. Prevalence of leading types of dietary supplements used in the Third National Health and Nutrition Examination Survey, 1988-94. Adv Data. 2004;1–7
  38. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281–286
  39. Gardiner P, Graham RE, Legedza A, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med. 2006;166:1968–1974
  40. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1–19
  41. Pinn G, Pallett L. Herbal medicine in pregnancy. Complement Ther Nurs Midwifery. 2002;8:77–80
  42. Cragan JD, Friedman JM, Holmes LB, Uhl K, Green NS, Riley L. Ensure the safe and effective use of medications during pregnancy: planning and prevention through preconception care. Matern Child Health J. 2006;10:S129–S135
  43. Black RA, Hill DA. Over-the-counter medications in pregnancy. Am Fam Physician. 2003;67:2517–2524

 Reprints not available from the authors.

 Conflict of Interest: Anne L. Dunlop, MD, MPH; Paula M. Gardiner, MD, MPH; Cynthia S. Shellhaas, MD, MPH; M. Kathryn Menard, MD, MPH; and Melissa A. McDiarmid, MD, MPH have no conflict of interest including grants, honoraria, advisory board membership, or share holdings.

PII: S0002-9378(08)00885-5

doi: 10.1016/j.ajog.2008.07.065

American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S367-S372 , December 2008

Article Tools